Arabinoxylan Alleviates Obesity by Regulating Gut Microbiota and Bile Acid Metabolism

Overweight and obesity are major and increasingly global public health concern. High intake of dietary fiber is negatively correlated with obesity and obesity-related metabolic diseases. Here, we investigated the impact of arabinoxylan on obesity based on the modification of gut microecology. Arabionxylan reduced body weight and improved glucose metabolism, as well as intestinal barrier function and metabolic endotoxemia in obese mice. Supplementation with arabinoxylan increased the relative abundance of <i>Prevotellaceae_UCG_001</i>, <i>Lachnospiraceae_NK4A136_group</i>, <i>Clostridia_UCG_014</i>, <i>Alistipes</i>, <i>Bacteroides</i>, and <i>Ruminococcus,</i> which was associated with the upregulated 7α-dehydroxylation function and production of secondary bile acids (deoxycholic acid and lithocholic acid). The modification of gut microbiota by arabinoxylan also influenced the production of SCFAs, genistein, daidzein, indolelactic acid, and indoleacetic acid, contributing to the amelioration of obesity. Our study highlights the antiobesity effects of arabinoxylan through the modification of gut microbiota and the production of bioactive metabolites.